WASHINGTON, January 14 - /EIN News/ While Pfizer is celebrating the approval of Lyrica as treatment for fibromyalgia, the medical profession has expressed its misgivings about the unhealthy relationship which has arisen between the Food and Drug Administration and the pharmaceutical industry. Many doctors are now complaining that the FDA has bowed to the interests of the latter by relaxing its criteria for defining what is a disease, allowing almost any affliction the status of "treatable disease" and thereby opening up new business avenues for the industry.

EINNews.com offers healthcare professionals free trials to this media monitoring service at http://health.einnews.com/users/register.php

"Chronic pain from chronic complainers" is how one doctor put it when asked to qualify the status of fibromyalgia in the eyes of many healthcare professionals. There are no biological tests to diagnose the disease, no environmental factors to identify, and nothing more than patient input to go by.

But Pfizer, followed by Eli Lilly and Forest Laboratories, have successfully lobbied the FDA into recognizing fibromyalgia as a disease, although there is no consensus in the medical profession regarding diagnosis. Instead, the pharmaceutical industry has been able to push ahead and find one more product to market to a sector of the population that is convinced it has this disease, while many doctors simply write off the chronic pain as nothing more than the consequences of a stressful lifestyle.

See also:

-- Latest Breaking Health News http://health.einnews.com/
-- Fibromyalgia News http://health.einnews.com/news/fibromyalgia
-- Lyrica News http://health.einnews.com/news/lyrica
-- Eli Lilly News http://health.einnews.com/news/eli-lilly
-- Forest Laboratories News http://health.einnews.com/news/forest-labs

The publisher of Healthcare Industry Today, EIN News, has been publishing since 1996 and ranks in Alexa's Top 10 list of online media services. We provide Internet data mining and search services to organizations, researchers and professional users who find them an indispensable source of latest news.

To learn more about our products, go to:
http://www.ipdgroup.com/freetrials.php

If you have any questions, comments, or need assistance signing up, please simply reply to this e-mail.

Feel free to forward this offer to any of your colleagues.

Best regards,

Subscription Department
IPD Group, Inc.
www.ipdgroup.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.